- Home
- KOD vs NVCT Comparison
KOD vs NVCT Comparison
Compare KOD & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- NVCT
- Stock Information
- Founded
- KOD 2009
- NVCT 2020
- Country
- KOD United States
- NVCT United States
- Employees
- KOD N/A
- NVCT N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- KOD Health Care
- NVCT Health Care
- Exchange
- KOD Nasdaq
- NVCT Nasdaq
- Market Cap
- KOD 186.3M
- NVCT 119.4M
- IPO Year
- KOD 2018
- NVCT 2022
- Fundamental
- Price
- KOD $8.72
- NVCT $4.52
- Analyst Decision
- KOD Hold
- NVCT Strong Buy
- Analyst Count
- KOD 5
- NVCT 1
- Target Price
- KOD $6.80
- NVCT $21.00
- AVG Volume (30 Days)
- KOD 473.7K
- NVCT 91.0K
- Earning Date
- KOD 11-14-2024
- NVCT 11-05-2024
- Dividend Yield
- KOD N/A
- NVCT N/A
- EPS Growth
- KOD N/A
- NVCT N/A
- EPS
- KOD N/A
- NVCT N/A
- Revenue
- KOD N/A
- NVCT N/A
- Revenue This Year
- KOD N/A
- NVCT N/A
- Revenue Next Year
- KOD N/A
- NVCT N/A
- P/E Ratio
- KOD N/A
- NVCT N/A
- Revenue Growth
- KOD N/A
- NVCT N/A
- 52 Week Low
- KOD $2.19
- NVCT $4.44
- 52 Week High
- KOD $11.60
- NVCT $12.10
- Technical
- Relative Strength Index (RSI)
- KOD 64.72
- NVCT 37.50
- Support Level
- KOD $8.03
- NVCT $4.48
- Resistance Level
- KOD $9.55
- NVCT $5.34
- Average True Range (ATR)
- KOD 0.89
- NVCT 0.37
- MACD
- KOD -0.08
- NVCT 0.07
- Stochastic Oscillator
- KOD 36.51
- NVCT 8.89
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.